Introduction of Biosimilar Rituximab: A Hospital Perspective

Introduction of Biosimilar Rituximab: A Hospital Perspective

Bibliographic Details
Main Author:	Simon Cheesman
Format:	Article
Language:	English
Published:	Wolters Kluwer 2021-01-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000515

Similar Items

Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
by: Carla Rognoni, et al.
Published: (2018-06-01)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
by: Arnold G. Vulto
Published: (2019-12-01)

Efficacy and safety of rituximab biosimilar in refractory lupus
by: Nantakarn Pongtarakulpanit, et al.
Published: (2020-12-01)

Safety of switching between rituximab biosimilars in onco-hematology
by: Silvana A. M. Urru, et al.
Published: (2021-03-01)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
by: Subramanian J, et al.
Published: (2017-04-01)

IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2018-11-01)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
by: Dawson, K., et al.
Published: (2021)

No impact of seronegativity on the efficacy of a biosimilar rituximab in biologic-naïve patients with active rheumatoid arthritis
by: Nedumooli Pottammal Jamshid, et al.
Published: (2019-01-01)

CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®
by: S. M. Alekseev, et al.
Published: (2015-04-01)

The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis
by: A S Avdeeva, et al.
Published: (2019-05-01)

Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
by: R. O. Dreval
Published: (2018-06-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
by: Yuankai Shi, et al.
Published: (2020-04-01)

The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond
by: Lin-Chau Chang
Published: (2019-07-01)

Biosimilars: Current regulatory perspective and challenges
by: Diwakar Jha, et al.
Published: (2013-01-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia
by: Alaa Fadhil Alwan, et al.
Published: (2020-12-01)

The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma
by: K D Kaplanov, et al.
Published: (2014-06-01)

Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar
by: Farzad Fatehi, et al.
Published: (2021-08-01)

Biosimilars: A novel perspective in diabetes therapy
by: Muthu Thiruvengadam, et al.
Published: (2020-01-01)

Biosimilars
Published: (2022)

Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa
by: Almaaytah A
Published: (2020-09-01)

THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
by: E. L. Nasonov, et al.
Published: (2017-09-01)

Biosimilars in India; current status and future perspectives
by: Bikash R Meher, et al.
Published: (2019-01-01)

Rituximab: historia, farmacología y perspectivas Rituximab: history, pharmacology and perspectives
by: Edgardo E. Espinosa Estrada, et al.
Published: (2010-12-01)

The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
by: M. A. Korolev, et al.
Published: (2021-01-01)

Estudos de medicamentos biosimilares Studies on biosimilar medications
by: Winston Bonetti Yoshida
Published: (2010-09-01)

Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting
by: Viktoriya Pavlych, et al.
Published: (2020-09-01)

Entry strategies into biosimilars: assessment of entry modes into the field of biosimilars from the perspective of pharmaceuticals, generics and biologics companies
by: Von Gehren, August Levin
Published: (2013)

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
by: Alexandra Azevedo, et al.
Published: (2018-09-01)

Biosimilars in Europe
Published: (2023)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018-09-01)

Perspective, perceptions, and promulgation of biosimilars: A questionnaire-based study to assess and understand the current challenges of biosimilars to the potential and intended users
by: Krishan Kumar Bhardwaj, et al.
Published: (2020-01-01)

Current perspective on rituximab in rheumatic diseases
by: Schioppo T, et al.
Published: (2017-10-01)

Dynamics of lymphocyte subpopulations, CD4+CD25+CD127- T regulatory cells in patients with rheumatoid arthritis during therapy with the rituximab biosimilar Acellbia
by: A. S. Avdeeva, et al.
Published: (2020-05-01)

Spanish Society of Hospital Pharmacy position paper on biosimilar medicines
by: Noemí Martínez-López de Castro, et al.
Published: (2018-07-01)

A RETROSPECTIVE EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF RITUXIMAB BIOSIMILAR (RTXM83) IN BRAZILIAN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
by: A.C.F. Cardoso, et al.
Published: (2020-11-01)

Biosimilars in pemphigus vulgaris
by: Sharmila Patil, et al.
Published: (2014-01-01)

Regulatory considerations for biosimilars
by: Ranjani Nellore
Published: (2010-01-01)